Daxor (DX5) Stock Overview

Engages in medical instrumentation and biotechnology operations. More details

DX5 fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	4/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 65.3% below our estimate of its fair value

Revenue is forecast to grow 95.28% per year

Earnings grew by 1609.7% over the past year

Risk Analysis

Makes less than USD$1m in revenue ($27K)

Highly volatile share price over the past 3 months compared to the German market

High level of non-cash earnings

Earnings are forecast to decline by an average of 133.1% per year for the next 3 years

+ 2 more risks

DX5 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW491,774 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

491,774 investors already sharing narratives

View all narratives

Daxor Corporation Competitors

Price History & Performance

Summary of share price highs, lows and changes for Daxor
Historical stock prices
Current Share Price	US$8.45
52 Week High	US$12.60
52 Week Low	US$7.40
Beta	0.26
1 Month Change	-9.63%
3 Month Change	6.96%
1 Year Change	6.96%
3 Year Change	-0.59%
5 Year Change	n/a
Change since IPO	3.05%

Recent updates

Shareholder Returns

	DX5	DE Medical Equipment	DE Market
7D	-2.3%	-1.3%	-2.5%
1Y	7.0%	-26.0%	-0.6%

Return vs Industry: DX5 exceeded the German Medical Equipment industry which returned -26% over the past year.

Return vs Market: DX5 exceeded the German Market which returned -0.6% over the past year.

Price Volatility

Is DX5's price volatile compared to industry and market?
DX5 volatility
DX5 Average Weekly Movement	13.7%
Medical Equipment Industry Average Movement	5.9%
Market Average Movement	5.4%
10% most volatile stocks in DE Market	12.7%
10% least volatile stocks in DE Market	2.8%

Stable Share Price: DX5's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: DX5's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
1971	n/a	Michael Feldschuh	www.daxor.com

Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973.

Daxor Corporation Fundamentals Summary

How do Daxor's earnings and revenue compare to its market cap?
DX5 fundamental statistics
Market cap	€53.76m
Earnings (TTM)	€8.03m
Revenue (TTM)	€23.38k

6.7x

P/E Ratio

2,299x

P/S Ratio

Is DX5 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DX5 income statement (TTM)
Revenue	US$26.69k
Cost of Revenue	US$0
Gross Profit	US$26.69k
Other Expenses	-US$9.14m
Earnings	US$9.17m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	1.57
Gross Margin	100.00%
Net Profit Margin	34,359.17%
Debt/Equity Ratio	0%

How did DX5 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/12 15:12
End of Day Share Price	2026/07/10 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Daxor Corporation is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Frank Takkinen	Lake Street Capital Markets, LLC
Scott Henry	Roth Capital Partners

Daxor (DX5) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Daxor Corporation Competitors

Eckert & Ziegler

Drägerwerk KGaA

Carl Zeiss Meditec

Ottobock SE KGaA

Price History & Performance

Recent News & Updates

New major risk - Share price stability

Insufficient new directors

Daxor Corporation, Annual General Meeting, Jun 23, 2026

Daxor Corporation Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data

Daxor Corporation Showcases Next-Generation Portable Blood Volume Analyzer At ACC.26

Daxor Corporation Showcases New Portable Blood Volume Analyzer

Recent updates

New major risk - Share price stability

Insufficient new directors

Daxor Corporation, Annual General Meeting, Jun 23, 2026

Daxor Corporation Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data

Daxor Corporation Showcases Next-Generation Portable Blood Volume Analyzer At ACC.26

Daxor Corporation Showcases New Portable Blood Volume Analyzer

Daxor Corporation Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee

Daxor Corporation has completed a Follow-on Equity Offering in the amount of $9.000007 million.

Daxor Corporation has filed a Follow-on Equity Offering in the amount of $9.000007 million.

Daxor Corporation Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA

Daxor Corporation's Blood Volume Analysis Validated for Covid and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care

Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System

Daxor Corporation, Annual General Meeting, Jun 24, 2025

Daxor Corporation Opens New BVA Program At A Premier Florida Healthcare Center in the Tampa Bay Region

Daxor Corporation Announces New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival

Daxor Corporation Submits 510(k) to FDA for Next-Generation Blood Volume Analyzer

Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals

Daxor Corporation Announces Multicenter Study Highlights Utility of Daxor's Blood Volume Analysis in Heart Failure Care

Daxor Corporation, Annual General Meeting, Jul 15, 2024

Nasdaq Staff Determines Daxor Complies with Nasdaq’s Audit Committee Requirement Set in Listing Rule 5605

Daxor Corporation Announces Two New Studies Validating the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion

New minor risk - Profit margin trend

New minor risk - Financial data availability

Daxor Corporation Announces New Data from Duke University Medical Center Validating the Benefits of Blood Volume Analysis

Investor sentiment deteriorates as stock falls 20%

New major risk - Share price stability

Daxor Corporation Submits Dual 510(K)/CLIA-Waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer

New minor risk - Share price stability

Daxor Corporation Announces the Presentation of Data from a Phase I National Institute of Health Sponsored Randomized Control Trial from Two Veterans Affairs Medical Centers

Daxor Corporation Announces New Data from Banner University Medicine Demonstrating Effectiveness of Bva-100 Use in Ambulatory Heart Failure Patients Presented At Heart Failure Annual Scientific Meeting

JACC-HF Reports Successful Heart Failure Trial with Daxor BVA-100®

Daxor Corporation Announces New Research Letter About Heart Failure Validating the Benefits of BVA-100 Diagnostic in Optimizing Individualized Therapy

Insufficient new directors

Daxor Corporation, Annual General Meeting, Jul 11, 2023

Daxor Corporation has completed a Follow-on Equity Offering in the amount of $4.000035 million.

Investor sentiment deteriorates as stock falls 21%

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorated over the past week

Daxor Corporation has completed a Follow-on Equity Offering in the amount of $2.000007 million.

Daxor Corporation Study Demonstrates Significant Clinical Utility of Daxor's Blood Volume (Bva-100(R)) Diagnostic in the Evaluation of Heart Failure

Daxor Corporation Announces New Data Validating Benefits of BVA-100 Diagnostic Blood Test in Reducing Hospital Length of Stay (LOS) for Heart Failure (HF) Patients

Daxor Corporation to Report Q2, 2022 Results on Aug 25, 2022

Daxor Corporation, Annual General Meeting, Jun 23, 2022

Daxor Corporation Announces New Data Demonstrating the Importance and Clinical Utility of Daxor’s Bva-100 Blood Test in Heart Failure (Hf) Patients Published in the Journal of Cardiac Failure

Daxor Corporation Announces Patient Enrollment Completion and Updates Data Analysis

Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Heart Failure Patients at Key Scientific Society Meeting

Shareholder Returns

Price Volatility

About the Company

Daxor Corporation Fundamentals Summary

Earnings & Revenue

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources